Trials / Completed
CompletedNCT00705172
Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome
Efficacy and Safety of Norditropin® (Somatropin) in Children With Prader-Willi Syndrome (PWS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 41 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Europe. The aim of this observational study is to collect data from children with Prader-Willi Syndrome, who have been treated off-label with Norditropin® for more than 12 months to seek approval for Norditropin® treatment with Prader-Willi Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somatropin | Prader-Willi syndrome children treated with at least one dose of Norditropin® |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-06-25
- Last updated
- 2023-11-02
Locations
3 sites across 3 countries: Denmark, Germany, Switzerland
Source: ClinicalTrials.gov record NCT00705172. Inclusion in this directory is not an endorsement.